Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Go back to Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™| Otter Lake Resources, Inc. New (NASDAQ: OTLK) | Delayed: 0.67 +0.02 (3.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $0.03 | |||
| Open | $0.69 | 52 Week Low | $0.01 | |||
| Day High | $0.69 | P/E | N/A | |||
| Day Low | $0.65 | EPS | $0.00 | |||
| Volume | 1,901,368 | |||||
